Monika Zajkowska1, Ewa Gacuta2, Sylwia Kozłowska3, Emilia Lubowicka4, Edyta K Głażewska4, Lech Chrostek5, Maciej Szmitkowski5, Przemysław Pawłowski6, Monika Zbucka-Krętowska7, Sławomir Ławicki5. 1. Department of Biochemical Diagnostics, Medical University of Bialystok, Bialystok, Poland. Electronic address: monika@zajkowska.com. 2. Department of Perinatology, Medical University of Bialystok, Bialystok, Poland. 3. Department of Laboratory Diagnostics, Public Health Care Hospital, Bialystok, Poland. 4. Department of Esthetic Medicine, Medical University of Bialystok, Bialystok, Poland. 5. Department of Biochemical Diagnostics, Medical University of Bialystok, Bialystok, Poland. 6. Department of Medical Pathomorphology, Medical University of Bialystok, Bialystok, Poland. 7. Department of Department of Re-productivness and Gynecological Endocrinology, Medical University of Bialystok, Bialystok, Poland.
Abstract
PURPOSE: Vascular endothelial growth factor is an important factor in promoting angiogenesis in malignant processes, matrix metalloproteinase-9 in the degradation of extracellular matrix, which enhances metastasis, and tissue inhibitor of metalloproteinase-1 is its inhibitor. The aim of this study was to investigate the diagnostic power of these parameters in comparison to CA15-3 in breast cancer patients and in relation to the control group. MATERIALS/ METHODS: The study included 120 breast cancer patients, 60 patients with benign breast tumors and 60 healthy women. Plasma levels of tested parameters were determined by enzyme-linked immunosorbent assay, CA15-3 by chemiluminescent microparticle immuno assay. RESULTS: Tissue inhibitor of metalloproteinase-1 showed the highest value of sensitivity in breast cancer group (86.25%) and, more importantly, highest value in breast cancer stage I (85%). Vascular endothelial growth factor also showed high sensitivity (stage I and II-75%, III-85%, IV-70% and 76.25% in total breast cancer group) and the highest specificity (85%) from all tested parameters. It was also the only parameter which had statistically significant area under curve in all stages. In the total breast cancer group all tested parameters showed statistically significant area under curve, but the maximum range was obtained for combination: 'vascular endothelial growth factor + CA15-3'. Vascular endothelial growth factor seems to be the best candidate for diagnosing breast cancer stage I and for differentiating between breast cancer and non-carcinoma cases. CONCLUSIONS: The combined analysis of tested parameters and CA15-3 resulted in an increase in sensitivity and area under curve values, which provides hope for developing new panel of biomarkers that may be used in diagnosing breast cancer in the future.
PURPOSE:Vascular endothelial growth factor is an important factor in promoting angiogenesis in malignant processes, matrix metalloproteinase-9 in the degradation of extracellular matrix, which enhances metastasis, and tissue inhibitor of metalloproteinase-1 is its inhibitor. The aim of this study was to investigate the diagnostic power of these parameters in comparison to CA15-3 in breast cancerpatients and in relation to the control group. MATERIALS/ METHODS: The study included 120 breast cancerpatients, 60 patients with benign breast tumors and 60 healthy women. Plasma levels of tested parameters were determined by enzyme-linked immunosorbent assay, CA15-3 by chemiluminescent microparticle immuno assay. RESULTS: Tissue inhibitor of metalloproteinase-1 showed the highest value of sensitivity in breast cancer group (86.25%) and, more importantly, highest value in breast cancer stage I (85%). Vascular endothelial growth factor also showed high sensitivity (stage I and II-75%, III-85%, IV-70% and 76.25% in total breast cancer group) and the highest specificity (85%) from all tested parameters. It was also the only parameter which had statistically significant area under curve in all stages. In the total breast cancer group all tested parameters showed statistically significant area under curve, but the maximum range was obtained for combination: 'vascular endothelial growth factor + CA15-3'. Vascular endothelial growth factor seems to be the best candidate for diagnosing breast cancer stage I and for differentiating between breast cancer and non-carcinoma cases. CONCLUSIONS: The combined analysis of tested parameters and CA15-3 resulted in an increase in sensitivity and area under curve values, which provides hope for developing new panel of biomarkers that may be used in diagnosing breast cancer in the future.
Authors: Diana C Márquez-Garbán; Manuel Gorrín-Rivas; Hsiao-Wang Chen; Colin Sterling; David Elashoff; Nalo Hamilton; Richard J Pietras Journal: Cancer Lett Date: 2019-02-13 Impact factor: 8.679
Authors: María Auxiliadora Olivares-Urbano; Carmen Griñán-Lisón; Mercedes Zurita; Rosario Del Moral; Sandra Ríos-Arrabal; Francisco Artacho-Cordón; Juan Pedro Arrebola; Amanda Rocío González; Josefa León; Juan Antonio Marchal; María Isabel Núñez Journal: J Cell Mol Med Date: 2019-09-30 Impact factor: 5.310